跳至主要内容
临床试验/NCT00325806
NCT00325806已完成4 期

Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.

Sanofi0 个研究点目标入组 1,008 人开始时间: 2000年5月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Sanofi
入组人数
1,008
主要终点
Mean systolic and diastolic 24-hour blood pressure in ABPM

研究概览

简要总结

Primary objective:

Mean values of systolic and diastolic office blood pressure

Secondary objectives:

Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • no previous antihypertensive therapy
  • high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)

排除标准

  • antihypertensive therapy
  • blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

结局指标

主要结局

Mean systolic and diastolic 24-hour blood pressure in ABPM

次要结局

  • Overall mortality and total number of cardiovascular and cerebro-vascular events
  • Changes in mean blood pressure readings over time
  • Reasons for admissions to hospital/-stays
  • Occurrence of pathological fasting glucose levels in serum/pathological HbA1c levels.

研究者

发起方
Sanofi
申办方类型
Industry
责任方
Sponsor

相似试验